Back
Bombay HC Delivers Knockout Blow to Faulty Drugs Prosecution: Delay, Missing Samples, and Procedural Blunders Seal Fate
In a scathing judgment, the has quashed criminal proceedings against a pharmaceutical firm and its partners under , slamming procedural lapses that robbed the accused of their statutory right to challenge a "" drug report. Justice N.J. Jamadar , in a detailed 30-page order pronounced on , ruled that delayed testing, failure to send a sample portion to the manufacturer, and a 's improper rendered the case an "."
The decision in and Ors. v. (Writ Petition No. 2777 of 2024) underscores strict compliance with sampling and testing timelines, echoing Supreme Court precedents on protecting manufacturers' reanalysis rights.
From Hospital Shelf to Courtroom Fiasco: The Sample That Took Years to Spark Trouble
The saga began on , when a Drugs Inspector from Dadra and Nagar Haveli inspected Vinoba Bhave Civil Hospital's Central Medical Store in Silvassa. He drew a sample of FEXINOL-12 (Fexofenadine Hydrochloride Tablets IP) , Batch No. CBT-400/16, manufactured by petitioner —a partnership firm based in Baddi, Himachal Pradesh—with partners as co-petitioners.
Sent to the the next day, the sample's report arrived only on —over seven months later—declaring it substandard. A show-cause notice traced the supply chain back to the petitioners. After a joint probe and sanction from the on , a complaint landed before the on . The court promptly issued process, bypassing Magistrate committal.
By filing time, the drug's shelf life (manufactured , expiry ) had lapsed over three years prior, dooming any retest possibility.
Petitioners Fire on All Cylinders: "Procedural Minefield Exploded Our Rights"
The petitioners unleashed a barrage of challenges: - violation : Testing delayed beyond the mandatory 60 days without extension sought from government. - breach : No sample portion sent to manufacturer despite awareness; notice under went to distributor , with just a copy to petitioners—who still requested a sample, ignored. - Lost retest right : Per , couldn't challenge analyst report; shelf-life expiry made court-held sample useless. - Mechanical process issuance : Special Judge didn't apply mind; no specific roles for partners under . - Jurisdictional overreach : Central Drugs Inspector lacked authority; Special Judge (Sessions-level) took , flouting .
They invoked Bombay HC priors like Quixotic Healthcare (2020) and Swapnil (2024), stressing delayed tests erode sample integrity.
Respondent's Defense Crumbles: "Standards Unavailable" Doesn't Cut It
The countered via affidavit: - Delay justified: Reference/impurity standards unavailable, needing procurement time. - Notice under served (); petitioners didn't notify intent to controvert report within 28 days. - Sanction valid; complaint details partners' roles in manufacturing/release.
But the court dismissed post-hoc excuses, insisting only a proviso extension suffices.
Court's Razor-Sharp Dissection: Precedents Pile Up Against Prosecution
Justice Jamadar dissected the Drugs Act's safeguards, prioritizing
's "peremptory" 60-day testing mandate.
"Delay beyond the specified period has the propensity to render the report of analysis suspect as the properties of the drugs may be lost,"
he noted, citing
Medipol Pharmaceutical
(2021 SCC) on valuable retest rights.
On sampling, mandates a portion to the manufacturer (disclosed under ). Drawing from Amery Pharmaceuticals (2001 SC), the court clarified distributors get notice, but manufacturers retain challenge avenues. Yet, Laborate Pharmaceuticals (2018 SCC) proved decisive: No sample sent + delayed complaint = "lame prosecution" post-shelf life.
? mandates Sessions-level trials but lacks override. Per v. Ashok Kumar Sharma (2021 SCC), Magistrate committal is essential absent express provision. A 2010 notification designating the didn't cover Section 27(d) offences.
Partners' liability under ? Complaint averments too "bald," per Brij Lal Mittal (1998 SC) and NI Act analogies—no specific conduct roles spelled out.
Integrating insights from legal reports, the ruling aligns with Bombay HC's consistent stance: Sessions Courts can't bypass for Drugs Act cases ( ).
Key Observations
"The provisions contained in of the , are ... Delayed analysis of the sample thus erodes the sanctity of the analysis."
"An invaluable right of the Petitioner No.1 to have the retesting of the sample was lost... the continuation of the prosecution... would be an ."
"No provision in the which expressly provides for the taking the cognisance of the offence... directly."
"The aforesaid averments do not strictly satisfy the requirement of spelling out the role of the Petitioner Nos.2 to 6."
Gavel Falls: Prosecution in Tatters, Roadmap for Drug Regulators
The petition succeeded emphatically:
"(i) The Writ Petition stands allowed. (ii) The impugned order dated 28 September 2021... stands quashed and set aside. (iii) The proceeding in Criminal Complaint, being Special Case No.32 of 2021, also stands quashed and set aside."
This precedent fortifies procedural rigor in drug prosecutions: Timely testing, sample delivery, and proper cognizance are non-negotiable. Manufacturers gain stronger shields against stale samples; regulators face pressure to streamline. Future cases may see more quashings on similar grounds, potentially easing frivolous probes while upholding public health vigilance.
